Broncus Holding

Broncus Holding Interest Coverage

The Interest Coverage Ratio of Broncus Holding (2216.HK) as of Nov 17, 2026 is -3.34. In the previous year, Interest Coverage Ratio was -6.53 — a change of -48.92% (higher).

Interest Coverage

-3.34

YoY

-48.92%

Last updated:

Interest Coverage Ratio of Broncus Holding is 2024 -3.34 . Interest Coverage Ratio of Broncus Holding was 2023 -6.53 . It decreases by -48.92% higher compared to the previous year.

The Broncus Holding Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2019
-102.83 USD
Jan 1, 2020
-97.43 USD
Jan 1, 2021
-5,117.38 USD
Jan 1, 2022
-9.26 USD
Jan 1, 2023
-6.53 USD
Jan 1, 2024
-3.34 USD
The Broncus Holding Interest Coverage history
YEARInterest CoverageYoY
-3.34-48.92%
-6.53-29.43%
-9.26-99.82%
-5,117.38+5,152.62%
-97.43-5.25%
-102.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Broncus Holding Stock analysis

What does Broncus Holding do? Broncus Holding Corp generates revenue through the sale of medical device and consumable products across multiple therapeutic areas. The company's diagnostic solutions include FleXNeedle, ATV Sheath, and ATV Balloon, targeting healthcare providers for diagnostic procedures. Lung cancer treatment solutions feature InterVapor for lung cancer and H-Marker, sold to hospitals and oncology centers. Chronic obstructive pulmonary disease (COPD) solutions consist of InterVapor for COPD and TLD Ablation System, marketed to respiratory care facilities. Navigation platforms like Lungpoint, Lungpro, and New Generation Navigation Platform are supplied to medical institutions requiring advanced imaging guidance. The firm's product portfolio is structured around four key solution areas: diagnostics, lung cancer treatment, COPD management, and navigation systems. Diagnostic tools such as FleXNeedle and ATV products are used in minimally invasive procedures, while InterVapor serves dual purposes for both lung cancer and COPD applications. The TLD Ablation System is specifically designed for COPD treatment, and navigation platforms support precise procedural guidance in respiratory interventions. Broncus Holding Corp's primary customers are healthcare institutions including hospitals, specialized oncology centers, and respiratory care facilities. These entities purchase the company's medical devices and consumables for clinical use in treating respiratory conditions. The company's commercialization strategy focuses on direct sales to medical facilities rather than through third-party distributors, ensuring consistent product application and support. Broncus Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Broncus Holding stock

Interest Coverage Ratio of Broncus Holding is -3.34 in 2024.

Interest Coverage Ratio of Broncus Holding changed from -6.53 to -3.34, representing a -48.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Broncus Holding since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Broncus Holding with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Broncus Holding

All Key Metrics — Broncus Holding